{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:35:10Z","timestamp":1791812110084,"version":"4.3.4"},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.det.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T08:25:48Z","timestamp":1562747148000},"page":"569-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["Review of Graft-Versus-Host Disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Vignesh","family":"Ramachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree S.","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay C.","family":"Strowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V68.3.770.770","article-title":"Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease","volume":"68","author":"Kernan","year":"1986","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib2","first-page":"107","article-title":"[Graft versus host disease after transfusion of blood and its products]","volume":"31","author":"Molaro","year":"1984","journal-title":"Riv Emoter Immunoematol"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.22227","article-title":"Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant","volume":"87","author":"Fidler","year":"2012","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.det.2019.05.014_bib4","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1097\/TP.0000000000001406","article-title":"Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management","volume":"100","author":"Murali","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2005.09.001","article-title":"Pathophysiology of graft-versus-host disease","volume":"43","author":"Ferrara","year":"2006","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.det.2019.05.014_bib7","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","article-title":"Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation","volume":"75","author":"Atkinson","year":"1990","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib8","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","article-title":"Treatment of moderate\/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome","volume":"75","author":"Weisdorf","year":"1990","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.det.2019.05.014_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00109-011-0767-x","article-title":"Danger signals activating innate immunity in graft-versus-host disease","volume":"89","author":"Zeiser","year":"2011","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hon.716","article-title":"Pathophysiology of acute graft-versus-host disease","volume":"21","author":"Reddy","year":"2003","journal-title":"Hematol Oncol"},{"issue":"18","key":"10.1016\/j.det.2019.05.014_bib12","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2011-03-340315","article-title":"Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORgammat in mice","volume":"118","author":"Yu","year":"2011","journal-title":"Blood"},{"issue":"1 Suppl","key":"10.1016\/j.det.2019.05.014_bib13","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.bbmt.2012.11.005","article-title":"Biology of graft-versus-host responses: recent insights","volume":"19","author":"MacDonald","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib14","first-page":"285","article-title":"Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best practice & research","volume":"26","author":"Sung","year":"2013","journal-title":"Clin Haematol"},{"issue":"26","key":"10.1016\/j.det.2019.05.014_bib15","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2012.09131.x","article-title":"Organ-specific management and supportive care in chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-017-0306-9","article-title":"Cutaneous graft-versus-host disease: diagnosis and treatment","volume":"19","author":"Strong Rodrigues","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.014_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1601-0825.2008.01448.x","article-title":"Oral graft-versus-host disease","volume":"14","author":"Imanguli","year":"2008","journal-title":"Oral Dis"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaad.2010.07.042","article-title":"Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions","volume":"65","author":"Byun","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib21","first-page":"367","article-title":"Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors","volume":"6","author":"Lerner","year":"1974","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1590\/abd1806-4841.20164180","article-title":"Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review","volume":"91","author":"Villarreal","year":"2016","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","article-title":"NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report","volume":"21","author":"Shulman","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.det.2019.05.014_bib26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"10.1016\/j.det.2019.05.014_bib27","doi-asserted-by":"crossref","first-page":"13ra2","DOI":"10.1126\/scitranslmed.3000406","article-title":"Elafin is a biomarker of graft-versus-host disease of the skin","volume":"2","author":"Paczesny","year":"2010","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood-2015-03-636753","article-title":"Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment","volume":"126","author":"McDonald","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.det.2019.05.014_bib29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/bmt.2015.191","article-title":"Identification and validation of biomarkers associated with acute and chronic graft versus host disease","volume":"50","author":"Ahmed","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib31","first-page":"19","article-title":"Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings","volume":"9","author":"Ringden","year":"1992","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib32","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","article-title":"A\u00a0randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis","volume":"16","author":"Perkins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","article-title":"A\u00a0prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation","volume":"34","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00063030-199809020-00003","article-title":"A\u00a0comparative review of methods for T cell depletion in the prophylaxis of graft-versus-host disease","volume":"9","author":"Hertenstein","year":"1998","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib36","first-page":"221","article-title":"Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients","volume":"7","author":"Ringden","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.det.2019.05.014_bib37","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1182\/blood-2004-10-4023","article-title":"New approaches for preventing and treating chronic graft-versus-host disease","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib38","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.det.2019.05.014_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.det.2019.05.014_bib40","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic\u00a0graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius","volume":"117","author":"Socie","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620717741860","article-title":"New and emerging therapies for acute and chronic graft versus host disease","volume":"9","author":"Hill","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib43","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.det.2019.05.014_bib44","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib45","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2011.10360.x","article-title":"German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD","volume":"165","author":"Marks","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","article-title":"Diagnosis and management of acute graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib49","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report","volume":"21","author":"Carpenter","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib50","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2014.04.009","article-title":"Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease","volume":"20","author":"Noce","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbmt.2011.06.001","article-title":"Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide\u2014an open, randomized, multicenter study","volume":"18","author":"Elad","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.det.2019.05.014_bib52","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2146\/ajhp120567","article-title":"Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease","volume":"70","author":"Park","year":"2013","journal-title":"Am J Health Syst Pharm"},{"issue":"2\u20133","key":"10.1016\/j.det.2019.05.014_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"issue":"9","key":"10.1016\/j.det.2019.05.014_bib54","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/archderm.137.9.1202","article-title":"Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients","volume":"137","author":"Choi","year":"2001","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.014_bib55","first-page":"946","article-title":"Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus","volume":"50","author":"Ziemer","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib56","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","article-title":"A\u00a0retrospective analysis of therapy for acute graft-versus-host disease: initial treatment","volume":"76","author":"Martin","year":"1990","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib58","first-page":"2288","article-title":"Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation","volume":"92","author":"Van Lint","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2019.05.014_bib59","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2014.118471","article-title":"Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial","volume":"100","author":"Mielcarek","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.det.2019.05.014_bib60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/2040620713490316","article-title":"Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion","volume":"4","author":"Hart","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib61","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bbmt.2013.04.018","article-title":"Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis","volume":"19","author":"Jagasia","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib62","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood.V96.7.2426","article-title":"Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study","volume":"96","author":"Greinix","year":"2000","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.det.2019.05.014_bib63","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.det.2019.05.014_bib64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bmt.2009.76","article-title":"Therapy with mycophenolate mofetil for refractory acute and chronic GVHD","volume":"44","author":"Furlong","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.det.2019.05.014_bib65","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood-2014-06-577023","article-title":"Phase 3 clinical trial of steroids\/mycophenolate mofetil vs steroids\/placebo as therapy for acute GVHD: BMT CTN 0802","volume":"124","author":"Bolanos-Meade","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.det.2019.05.014_bib66","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.bmt.1701281","article-title":"Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients","volume":"22","author":"Basara","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib68","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1016\/j.transproceed.2005.09.066","article-title":"Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells","volume":"37","author":"Park","year":"2005","journal-title":"Transpl Proc"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2005.05616.x","article-title":"Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease","volume":"130","author":"Couriel","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.det.2019.05.014_bib70","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","article-title":"Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease","volume":"72","author":"Benito","year":"2001","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.det.2019.05.014_bib71","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bbmt.2010.07.025","article-title":"Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors","volume":"17","author":"Jedlickova","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"10.1016\/j.det.2019.05.014_bib72","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbmt.2008.02.009","article-title":"Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors","volume":"14","author":"Furlong","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.det.2019.05.014_bib73","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2007.02.003","article-title":"Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease","volume":"13","author":"Jurado","year":"2007","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"10.1016\/j.det.2019.05.014_bib74","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib75","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/jid.2013.476","article-title":"Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib","volume":"134","author":"Okiyama","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-016-0298-6","article-title":"Ruxolitinib in steroid refractory graft-vs.-host disease: a case report","volume":"9","author":"Maffini","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"10.1016\/j.det.2019.05.014_bib77","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib78","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","article-title":"Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.bmt.1705440","article-title":"Assessing the potential role of photopheresis in hematopoietic stem cell transplant","volume":"38","author":"Greinix","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib80","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ad.2015.04.009","article-title":"An\u00e1lisis retrospectivo del papel de la fototerapia en la enfermedad injerto contra hu\u00e9sped cr\u00f3nica cut\u00e1nea. Revisi\u00f3n de la literatura","volume":"106","author":"Ballester-S\u00e1nchez","year":"2015","journal-title":"Actas Dermosifiliogr"},{"issue":"8","key":"10.1016\/j.det.2019.05.014_bib81","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2008.12.493","article-title":"First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate","volume":"15","author":"Wang","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib83","doi-asserted-by":"crossref","first-page":"515.e1-18","DOI":"10.1016\/j.jaad.2011.11.961","article-title":"Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease","volume":"66","author":"Hymes","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A\u00a0randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib85","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib86","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.det.2019.05.014_bib87","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","article-title":"Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD","volume":"122","author":"Olivieri","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2019.05.014_bib88","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/leu.2010.83","article-title":"Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia","volume":"24","author":"Nakasone","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.det.2019.05.014_bib89","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/bmt.2009.20","article-title":"Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?","volume":"44","author":"Breccia","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.det.2019.05.014_bib90","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/bmt.2009.368","article-title":"Development of severe sclerotic chronic GVHD during treatment with dasatinib","volume":"45","author":"Pulanic","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"11","key":"10.1016\/j.det.2019.05.014_bib92","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2010.026104","article-title":"Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study","volume":"95","author":"Kim","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib93","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.det.2019.05.014_bib94","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"21","key":"10.1016\/j.det.2019.05.014_bib95","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.det.2019.05.014_bib96","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2017-03-772210","article-title":"Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease","volume":"129","author":"Chen","year":"2017","journal-title":"Blood"},{"issue":"9419","key":"10.1016\/j.det.2019.05.014_bib97","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"issue":"9624","key":"10.1016\/j.det.2019.05.014_bib98","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib99","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/bmt.2008.316","article-title":"Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium","volume":"43","author":"von Bonin","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.det.2019.05.014_bib100","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease","volume":"81","author":"Ringden","year":"2006","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.det.2019.05.014_bib101","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2012.10","article-title":"Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels","volume":"26","author":"Leonhardt","year":"2012","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.det.2019.05.014_bib102","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.det.2019.05.014_bib103","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.det.2019.05.014_bib104","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2016-06-715284","article-title":"Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT","volume":"128","author":"Ryan","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.det.2019.05.014_bib105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.LBA-3.LBA-3","article-title":"Multicenter open-label phase 2 study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after failure of corticosteroids","volume":"128","author":"Miklos","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.det.2019.05.014_bib106","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib107","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex\u00a0vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbmt.2009.11.006","article-title":"Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report","volume":"16","author":"Zhou","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.det.2019.05.014_bib110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MOH.0b013e32834ba87d","article-title":"Treatment of chronic graft-versus-host disease in 2011","volume":"18","author":"Inamoto","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.det.2019.05.014_bib111","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib112","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V93.1.66","article-title":"Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease","volume":"93","author":"Marcellus","year":"1999","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.det.2019.05.014_bib113","first-page":"1438","article-title":"Low-dose methotrexate as salvage therapy for\u00a0refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"91","author":"de Lavallade","year":"2006","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.det.2019.05.014_bib114","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/bmt.2012.16","article-title":"Successful treatment of a refractory skin ulcer in chronic cutaneous GvHD after allogeneic HSCT with split-thickness skin allografting from the stem cell donor","volume":"47","author":"Ammer","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.det.2019.05.014_bib115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007890-198508000-00027","article-title":"Tolerance to donor-type skin in the recipient of a bone marrow allograft. Treatment of skin ulcers in chronic graft-versus-host disease with skin grafts from the bone marrow donor","volume":"40","author":"Knobler","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.det.2019.05.014_bib116","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/bmt.2017.53","article-title":"Skin allograft for severe chronic GvHD","volume":"52","author":"Crocchiolo","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.det.2019.05.014_bib117","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.det.2019.05.014_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2009.00577.x","article-title":"Many faces of graft-versus-host disease","volume":"51","author":"Penas","year":"2010","journal-title":"Australas J Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:42:23Z","timestamp":1760006543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863519300567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0733863519300567"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2019.05.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Graft-Versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}